References

nid

Нефрология и диализ

Nephrology and Dialysis

1680-44222618-9801

Российское диализное общество

nid-1359

Research Article

ШКОЛА НЕФРОЛОГА

EDUCATIONAL MATERIALS

Роль циклоспорина в лечении волчаночного нефрита (Обзор литературы и два наблюдения)

Role of cyclosporin in treatment of lupus nephritis (Review and case report)

Захарова

Е. В.

Zakharova

E. V.

zakharoval@mtu-net.ru

Московская городская клиническая больница имени С.П. Боткина, г. МоскваRussian Federation

2007

23062025

92192197

2025

Захарова Е.В.

Zakharova E.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.nephro.ru/jour/article/view/1359

Поражение почек является одним из наиболее частых и серьезных проявлений системной красной волчанки (СКВ), преобладающим вариантом является волчаночный нефрит (ВН), который выявляется у 25-50% больных уже к моменту установки диагноза. В целом частота ВН достигает у взрослых пациентов 60-70%, а гистологические изменения обнаруживается у 90% больных

волчаночный нефритиммуносупрессивная терапияциклоспорин

References1

Захарова Е.В. Прогнозирование исходов системной красной волчанки и системных васкулитов с экстраренальными и почечными проявлениями. Дисс…к.м.н. М.: 2005: 94-109.

Тареева И.Е., Швецов М.Ю., Краснова Т.Н. и др. Артериальная гипертензия при волчаночном нефрите. Тер. Арх. 1997; 6: 13-17.

Тареева И.Е., Шилов Е.М., Краснова Т.Н. и др. Волчаночный нефрит в середине XX века и в начале XXI века. Тер. Арх. 2001; 6: 5-10.

Шилов Е.М. Иммунодепрессивная терапия активных форм нефрита. Автореф. дисс…д.м.н. М.: 1994: 34-44.

Шилов Е.М. Волчаночный нефрит: стратегия лечения. Тер. Арх. 2006; 5: 76-82.

Appel G.B., Cohen D.J., Pirani C.L. et al. Long-Term follow-up of patients with lupus nephritis. Am J Med 1987; 83: 877-885.

Atkins R. Lupus Erythematosus: Lupus nephritis. Нефрология и диализ 2001; 3: 84-88.

Austin III H.A., Kippel J.H., Balow J.E. et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Eng J Med 1986; 314: 614-619.

Austin III H.A., Vaughan E.M., Boumpas D.T. et al. Lupus membranous nephropathy: controlled trial of prednisone, pulse cyclophosphamide, and cyclosporine. Am J Soc Nephrol 2000; 11: 439.

Bansal V.K., Beto J.A. Treatment of lupus nephritis: A meta-analysis of clinical trials. Amer. J Kidney Dis 1997; 29: 193-199.

Boumpas D.T., Austin III H.A., Vaughan E.M. et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. The Lancet 1992; 340: 741-745.

Cameron J.S. Lupus Nephritis. J Am Soc Nephrol 1999; 10: 413-424.

Cervera R., Khamasta M.A., Font J. et al. Morbidity and mortality in systemic lupus etythematosus during a 5-year period: a multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Etythematosus. Medicine. Baltimore 1999; 78: 165-167.

Chun T.M., Li F.K., Tang C.S.O. Efficacy of mycofenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1165-1162.

Chun T.M., Li F.K., Hao W.K. et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequental immunosupression, Lupus 1999; 8: 545-551.

Churg J., Sobin L. Lupus nephritis. In Renal Disease. Tokio; Igakou-Schoin 1982: 127-131.

Contreras G., Pardo V., Leclercq B. et al. Sequential Therapies for Proliferative Lupus Nephritis. New Engl J Med 2004; 350: 971-980.

Conteras G., Tomzan E., Nahar N. et al. Maintenance therapies for proliferative lupus nephritis: mycophenolate mophetil, azathioprin and intravenous cycliphosphamide. Lupus 2005; 14: 890-895.

Donadio J.V. Treatment of membranous nephropaty in systemic lupus erythematosus. Nephrol Dial Trasplant 1992; (Suppl 1): 97-104.

Dostal C., Tesar V., Rychlik I. et al. Effect of 1-year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998; 7: 29-36.

Enriques R., Tovar J.V., Amoros F. et al. Can cyclosporin be used without steroids in systemic lupus erythematosus? Nephron 1991; 57: 367-368.

Favre H., Miescher A., Huang Y.P. et al. Cyclosporine in treatment of lupus nephritis. Am J Nephrol 1989; 9: 57-60.

Ferrario L., Bellone M., Bozzolo E. et al. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rheumatology 2000; 39: 218-220.

Feutren H., Querin S., Noel L.H. et al. Effects of cyclosporin in severe systemic lupus erythematosus. J Pediatr 1987; 111: 1063-1068.

Fu L.W., Yang L.Y., Chen W.P. et al. Clinical efficacy of cyclosporin: a neural in the treatment of pediatric lupus nephritis with heavy proteinuria. Br J Rheum 1998; 37: 217-221.

Gourley M.F., Austin III H.A., Scott D. et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Int Med 1996; 125: 549-557.

Hallegua D., Wallace D.J., Metzger A.L. et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of literature. Lupus 2000; 9: 241-251.

Halevy D., Radhakrishnan J. Cyclosporin in treatment of glomerular diseases. Exp Opin Invest Drugs 2000; 9: 1053-1063.

Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus etythematosus [letter]. Arthr Rheum 1997; 40: 1725.

Houssiau F.A., Vasconcelos C., D’Cruz D. et al. Efficacy and safety of short course intravenous pulse cyclophosphamide regimen in proliferative lupus nephritis: interim analysis of Euro-Lupus Nephritis Trial. Lupus 2001; 10: 94.

Hussien M.M., Mooij J.M., Roujouleh H. Cyclosporin in treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol 1993; 40: 160-163.

Illei G.G., Austin H.A., Crane M. et al. Combination therapy with pulse cyclophosphamide plus pulse methyl-prednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 296-98.

Kolasinski S.L., Chung J.B., Albert D.A. What do we know about lupus membranous nephropathy? An analytic review. Arthr Rheum 2002; 47: 450-455.

Leehey D.J., Katz A.I., Azaran A.H. et al. Silent diffuse lupus nephritis: long-term follow-up. Am J Kidney Dis 1983; 2: 188-196.

Lefrancois N., Deteix P., Laville M. et al. Treatment of systemic lupus with cyclosporin A: a patient with a one-year follow-up. Kidney Int 1984; 26: 160-163.

Miescher P.A., Miescher A. Combined cyclosporin-streoid treatment of systemic lupus erythematous. In: Cyclosporin in autoimmune disease. R. Schindler (Ed), Springer-Verlag, Berlin 1985: 334.

Miescher P.A., Favre H., Mihatsch M.J. et al. The place of cyclosporin A in the treatment of connective tissue diseases. Transplant Proc 1994; suppl 4: 224-237.

Mok C.C., Ying K.Y., Lau C.S. et al. Treatment of Pure Membranous Lupus Nephropathy With Prednisone and Azathioprine: An Open-Lable trial. An J Kidney Dis 2004; 43: 269-276.

Moroni G., Maccario M., Banfi G. et al. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998; 31: 681-686.

Nossent H.C., Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephitis. Rheumatology 2000; 39: 969-974.

Ponticelli C. Current treatment recommendation for lupus nephritis. Drugs 1990; 40: 537-550.

Ponticelli C. Treatment of proliferative lupus nephritis. Acta Nephrologica 2005; 19 (2): 47-52.

Radhakrishnan J., Szabolcs M., D’Agati V. et al. Lupus membranous nephropathy (LMN): Course and prognosis in 50 patients. Am J Soc Nephrol 1993: 284 (Abstract).

Radhakrishnan J., Kunis C.L., D’Agati V. et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147-154.

Steinberg A.D., Muir J., Scott D.E. et al. Approach to lupus nephritis based upon randomized trials. Contrib Nephrol 1992; 99: 46-54.

Tam L.S., Li E.K., Szeto C.C. et al. Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporine A. Lupus 2001; 10: 827-829.

Tam L.S., Li E.K., Leung C.V. et al. Long term treatment of lupus nephritis with cyclosporin A. QJM 1998; 91: 573-580.

Tokuda M., Kurata N., Mizoguchi A. et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthr Rheum 1994; 37: 551-558.

Uramoto K.M., Michet C.J., Thumboo J. et al. Trends in the incidence and mortality of systemic lupus etythematosus 1950-1992. Arthr Rheum 1999; 42: 46-50.

Urowitz M.B., Gladman D.D., Abu-Shakra M. et al. Evolving spectrum of mortality and morbidity in SLE. Lupus 1999; 8: 253-255.

Valery A., Radhakrishnan J, Estes D. et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42: 71-78.

Weening J.J., D’Agati V.M., Schwartz M.M. et al. The classification of glomerulonephtitis in systemic lupus etythematosus revisited. J Am Soc Nephrol 2004; 15: 241-251.

Weening J.J., D’Agati V.M., Schwartz M.M. et al. The classification of glomerulonephtitis in systemic lupus etythematosus revisited. Kidney Int 2004; 65: 521-530.

The authors declare that there are no conflicts of interest present.